Isofol Medical
Business Services · Sweden · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Arvid Wallgrens Backe Biotech Center 20,...Phone Number
+46 31137331Website
www.isofolmedical.comRevenue
-Industry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Isofol Medical
Isofol Medical AB (publ) is a biotechnology company located in Gothenburg, Sweden, that focuses on developing innovative drug candidates for advanced colorectal cancer treatment. Their primary product, arfolitixorin, aims to enhance the efficacy of standard therapies for solid tumors, addressing the significant need for improved cancer treatments. The company is currently conducting a phase Ib/II clinical study to optimize the drug candidate's dosing regimen. Isofol is publicly traded on Nasdaq Stockholm and aims to improve cancer prognosis for patients globally.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Isofol Medical your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Isofol Medical launches new products
Check if Isofol Medical has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Isofol Medical has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Isofol Medical had a recent Job posting/layoffs
Check out if Isofol Medical is spiking on competitors!
Isofol Medical, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Isofol Medical
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Isofol Medical recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Isofol Medical as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Isofol Medical is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Isofol Medical is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Isofol Medical.
Isofol Medical financials insights
Gather financial insights about Isofol Medical, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Stock/Share Issuance
$8.7M
Isofol Medical Tech Stack
A closer look at the technologies used by Isofol Medical
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company
Isofol Medical News & Media
The Board of Directors of Isofol resolves on a fully guaranteed Rights Issue of units ... - TradingView
GOTHENBURG, Sweden, 12 May 2025 – The Board of Directors of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol” or the “Company”) has today resolved on a new issue of units with preferential rights for the Company’s existing shareholders amounting to approximately SEK 85 million before is…Isofol appoints Magdalena Hagman as new Chief Financial Officer - Placera
GOTHENBURG, Sweden, July 30, 2024 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announced today that the company has appointed Margareta Hagman as the nIsofol Medical AB (publ) publishes year-end report, January – December 2023
GOTHENBURG, Sweden, February 20, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's year-end report for January – December 2023 is now available on the company's website, www.isofolmedical.com. The information in the press release is intended for investors. Fourth quarter, October – December 2023 · Net revenue amounted to kSEK 0 (1,857) and other revenue to kSEK 0 (0) · The result for the period amounted to kSEK -8,883 (-25,284)Isofol’s Board of Directors decides to initiate the planning of clinical studies and will announce a strategic development plan on March 19
GOTHENBURG, Sweden, February 14, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), has been engaged in intensive strategy work since the new Board of Directors and management took office in January. The Board of Directors has decided today to prepare a new development program for arfolitixorin, with the goal of initiating new clinical studies as soon as possible. The company intends to present details of the strategic direction on March 19, along with holding
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Isofol Medical
Sign Up For FreeTo access detailed company insights
Isofol Medical AB (publ) is a biotechnology company located in Gothenburg, Sweden, that focuses on developing innovative drug candidates for advanced colorectal cancer treatment. Their primary product, arfolitixorin, aims to enhance the efficacy of standard therapies for solid tumors, addressing the significant need for improved cancer treatments.... Read More
